Hemodynamic characterization of a novel neuropeptide Y receptor antagonist

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 5, 1996, Pages 712-718

  Tadepalli, Anjaneyulu S ^a   Harrington, W Wallace ^a,b   Hashim, Mir A ^a   Matthews, Jessica ^a   Leban, Johann J ^b   Spaltenstein, Andrew ^b   Daniels, Alejandro J ^a  

^a Department of Pharmacology ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

1229U91; Dogs; Hypertension; NPY; Rats; Receptor antagonist; Renovascular

Indexed keywords

GR 231118; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HEMODYNAMICS; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANESTHESIA; ANIMALS; CYSTAMINE; DOGS; HEMODYNAMIC PROCESSES; HYPERTENSION; PEPTIDES, CYCLIC; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y;

EID: 0030010196     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199605000-00014     Document Type: Article

References (37)

1. Tatemoto KM, Carlquist M, Mutt V. Neuropeptide Y. A novel brain peptide with structural similarities to peptide YY and pancreatic peptide. Nature 1982;296:659-60.
2. Allen YS, Adrian TE, Allen JM, et al. Neuropeptide Y distribution in human brain. Science 1983;221:877-9.
3. Adrian TE, Allen JM, Bloom SR, et al. Neuropeptide Y distribution in human brain. Nature 1983;306:584-6.
4. Lundberg JM, Terenius L, Hokfelt T, et al. Neuropeptide Y (NPY) immunoreactivity in peripheral noradrenergic neurons and the effects of NPY on sympathetic function. Acta Physiol Scand 1982; 116:477-80.
5. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regnl Peril 1984;8:225-35.
6. Pernow J, Lundberg JM. Release and vasoconstrictor effects of neuropeptide Y in relation to non-adrenergic and sympathetic control of renal blood flow in the pig. Acta Physiol Scand 1989;136: 507-16.
7. Edvinsson L, Hakanson R, Wahlestedt C, Uddman R. Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol Sci 1987;8:231-5.
8. Lundberg JM, Saria A, Anggard A, Hokfelt T, Terenius L. Neuropeptide Y and noradrenaline interaction in peripheral cardiovascular control. Clin Exp Theory Pract 1984;A6:1961-72.
9. Awad SJ, Einstein R, Potter EK, Richardson DP. The effects of neuropeptide Y on myocardial contractility and coronary blood flow. Br J Pharmacol 1991;104:195-201.
10. Zukowska-Grojec Z, Wahlestedt C. Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Wahlestedt C, eds. The biology of neuropeptide Y and related peptides. Totowa, NJ: Humana Press, 1993:315-88.
11. Edvinsson L, Ekblad E, Hakanson R, Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 1984;83:519-25.
12. Lopez LF, Perez A, St-Pierre S, Huidobro-Toro JP. Neuropeptide tyrosin (NPY)-induced potentiation of pressor activity of catecholamines in conscious rats. Peptides 1987;10:551-8.
13. Aubert JF, Waeber B, Rossier B, Geering K, Nussberger J, Brunner HR. Effects of neuropeptide Y on the blood pressure response to various vasoconstrictor agents. J Pharmacol Exp Ther 1988; 246:1088-92.
14. Mabe Y, Tatemoto K, Huidobro-Toro JP. Neuropeptide Y-induced pressor responses: activation of a non-adrenergic mechanism, potentiation by reserpine and blockade by nifedipine. Eur J Pharmacol 1985;116:33-9.
15. Grundemar L, Sheikh SP, Wahlestedt C. Characterization of receptor types for neuropeptide Y and related peptides. In: Colmers WF, Wahlestedt C, eds. The biology of neuropeptide Y and related peptides. Totowa, NJ: Humana Press, 1993:197-239.
16. Grundemar L, Hakanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci 1994;15: 153-9.
17. Tatemoto K, Mann MJ, Shimuju M. Synthesis of receptor antagonists of neuropeptide Y. Proc Natl Acad Sci USA 1992;89:1174-8.
18. 3H]neuropeptide Y displacement activity. J Med Chem 1993;36: 272-9.
19. 2 receptor. J Med Chem 1994;37:2242-8.
20. Sun XY, Dahlof C, Edvinsson L, Hedner T. D-Myo-inositol-1,2,6-triphosphate is a selective antagonist of neuropeptide Y (NPY)-induced pressor response in the pithed rat. Eur J Pharmacol 1991; 204:281-6.
21. Feth F, Erdbrugger W, Rasher W, Michel MC. Is PP56 (D-myo-inositol-1,2,6-triphosphate) an antagonist at neuropeptide receptors? Life Sci 1993;52:1835-44.
22. Daniels AJ, Mathews JE, Slepetis RJ, et al. Novel high-affinity neuropeptide Y receptor antagonists. Proc Natl Acad Sci USA 1995;92:9067-71.
23. Doughty MB, Chu SS, Miller DW, Li K, Tessel R. Benextramine: a long lasting neuropeptide Y receptor antagonist. Eur J Pharmacol 1990;185:113-4.
24. Hashim MA, Tadepalli AS. Hemodynamic responses evoked by endothelin from central cardiovascular neural substrates. Am J Physiol 1992;262:H1-9.
25. 2 type of NPY receptors. Soc Neurosci Ahstr 1995;21:1593.
26. Doughty MB, Li K, Chu SS, Tessel R. Benextramine-neuropeptide Y (NPY) binding site interactions: characterization of 3H-NPY binding site in rat brain. Neuropeptides 1992;23:169-80.
27. Balasubramaniam A, Sheriff S, Johnson ME, et al. [D-Trp32]-neuropeptide Y: a competitive antagonist of NPY in the hypothalamus. J Med Chem 1994;37:811-5.
28. 1 receptor antagonist BIBP3226. Eur J Pharmacol 1994;271:R11-3.
29. 1 receptor antagonist. FEBS Lett 1995;362:192-6.
30. Westfall TC, Han SP, Knuepfer M, et al. Neuropeptides in hypertension: role of neuropeptide Y and calcitonin gene regulated peptide. Br J Clin Pharmacol 1990;30:75S-82S.
31. Tabarin A, Minot AP, Dallochio M, Roger P, Ducassou D. Plasma concentration of neuropeptide Y in patients with adrenal hypertension. Regul Pept 1992;42:51-61.
32. Erlinge D, Ekman R, Thulin T, Edvinsson L. Neuropeptide Y-like immunoreactivity in hypertension. J Hypertens 1992;10:1221-5.
33. Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens 1990;3:823-8.
34. Ogawa T, Kitamura K, Kangawa K, Matsuo H, Eto T. Platelet neuropeptide Y in spontaneously hypertensive rats. J Hypertens 1992;10:765-71.
35. Miller DW, Tessel RE. Age-dependent hyperresponsiveness of spontaneously hypertensive rats to the pressor effects of intravenous neuropeptide Y (NPY): role of mode of peptide administration and plasma NPY-like immunoreactivity. J Cardiovasc Pharmacol 1991;18:647-56.
36. Zukowska-Grojec Z, Golczynska M, Shen GH, et al. Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr Nephrol 1993;7:845-52.
37. Daly RN, Roberts MI, Ruffalo RR, Hieble JP. The role of neuropeptide Y in vascular sympathetic neurotransmission may be enhanced in hypertension. J Hypertens 1988;6(suppl 4):S535-8.